⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKBA News
Akebia Therapeutics, Inc.
Form 8-K
sec.gov
AKBA
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
globenewswire.com
AKBA
Form 8-K
sec.gov
AKBA
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
globenewswire.com
AKBA
Form 8-K
sec.gov
AKBA
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
globenewswire.com
AKBA